Catherine Schulte
Stock Analyst at Baird
(3.51)
# 573
Out of 5,182 analysts
136
Total ratings
50%
Success rate
4.84%
Average return
Main Sectors:
Stocks Rated by Catherine Schulte
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TMO Thermo Fisher Scientific | Maintains: Outperform | $653 → $639 | $470.22 | +35.89% | 29 | Apr 24, 2026 | |
| DHR Danaher | Maintains: Outperform | $249 → $245 | $178.98 | +36.89% | 13 | Apr 22, 2026 | |
| CAI Caris Life Sciences | Maintains: Outperform | $26 → $28 | $18.44 | +51.84% | 2 | Feb 27, 2026 | |
| GRAL GRAIL | Maintains: Outperform | $113 → $82 | $52.20 | +57.09% | 2 | Feb 20, 2026 | |
| TEM Tempus AI | Initiates: Outperform | $59 | $51.10 | +15.46% | 1 | Feb 17, 2026 | |
| GH Guardant Health | Initiates: Outperform | $120 | $83.09 | +44.42% | 1 | Feb 17, 2026 | |
| A Agilent Technologies | Maintains: Outperform | $142 → $165 | $114.87 | +43.64% | 18 | Nov 25, 2025 | |
| AVTR Avantor | Maintains: Outperform | $15 → $17 | $7.86 | +116.28% | 14 | Oct 24, 2025 | |
| MTD Mettler-Toledo International | Maintains: Neutral | $1,210 → $1,230 | $1,262.48 | -2.57% | 10 | Aug 4, 2025 | |
| MRVI Maravai LifeSciences Holdings | Maintains: Neutral | $3 → $2 | $3.56 | -43.74% | 6 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $41 | $34.02 | +20.37% | 4 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $88 → $68 | $53.51 | +27.08% | 11 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $38 | $24.69 | +53.91% | 7 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $56 → $33 | $59.15 | -44.21% | 3 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $335 → $281 | $126.92 | +121.40% | 7 | Sep 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $208 → $217 | $300.73 | -27.84% | 7 | Oct 30, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $20 | $200.17 | -90.01% | 1 | Jun 28, 2018 |
Thermo Fisher Scientific
Apr 24, 2026
Maintains: Outperform
Price Target: $653 → $639
Current: $470.22
Upside: +35.89%
Danaher
Apr 22, 2026
Maintains: Outperform
Price Target: $249 → $245
Current: $178.98
Upside: +36.89%
Caris Life Sciences
Feb 27, 2026
Maintains: Outperform
Price Target: $26 → $28
Current: $18.44
Upside: +51.84%
GRAIL
Feb 20, 2026
Maintains: Outperform
Price Target: $113 → $82
Current: $52.20
Upside: +57.09%
Tempus AI
Feb 17, 2026
Initiates: Outperform
Price Target: $59
Current: $51.10
Upside: +15.46%
Guardant Health
Feb 17, 2026
Initiates: Outperform
Price Target: $120
Current: $83.09
Upside: +44.42%
Agilent Technologies
Nov 25, 2025
Maintains: Outperform
Price Target: $142 → $165
Current: $114.87
Upside: +43.64%
Avantor
Oct 24, 2025
Maintains: Outperform
Price Target: $15 → $17
Current: $7.86
Upside: +116.28%
Mettler-Toledo International
Aug 4, 2025
Maintains: Neutral
Price Target: $1,210 → $1,230
Current: $1,262.48
Upside: -2.57%
Maravai LifeSciences Holdings
May 13, 2025
Maintains: Neutral
Price Target: $3 → $2
Current: $3.56
Upside: -43.74%
Apr 21, 2025
Maintains: Neutral
Price Target: $40 → $41
Current: $34.02
Upside: +20.37%
Feb 19, 2025
Downgrades: Neutral
Price Target: $88 → $68
Current: $53.51
Upside: +27.08%
Mar 1, 2023
Maintains: Outperform
Price Target: $42 → $38
Current: $24.69
Upside: +53.91%
Nov 21, 2022
Maintains: Outperform
Price Target: $56 → $33
Current: $59.15
Upside: -44.21%
Sep 22, 2020
Maintains: Neutral
Price Target: $335 → $281
Current: $126.92
Upside: +121.40%
Oct 30, 2019
Maintains: Neutral
Price Target: $208 → $217
Current: $300.73
Upside: -27.84%
Jun 28, 2018
Maintains: Outperform
Price Target: $17 → $20
Current: $200.17
Upside: -90.01%